Reports Outline Irritable Bowel Syndrome Study Findings from University of Chile (Limosilactobacillus reuteri DSM 17938 and ATCC PTA 6475 for the treatment of moderate to severe irritable bowel syndrome in adults: a randomized controlled trial).

A recent study conducted by researchers at the University of Chile aimed to determine the efficacy and safety of Limosilactobacillus reuteri (L. reuteri) DSM 17938 combined with L. reuteri ATCC PTA 6475 in improving symptoms associated with irritable bowel syndrome (IBS) in adults. The study involved 140 adults diagnosed with IBS and found that the intervention of L. reuteri significantly improved IBS-associated symptoms, stool consistency, and symptoms associated with anxiety after 6 weeks. The study concluded that a 14-week intervention of L. reuteri is safe and effective in reducing symptoms of IBS in adults aged 18 to 65 years. [Extracted from the article]

Copyright of Clinical Trials Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)